Clinical trials · St. Louis, MO
Lymphoma clinical trials in St. Louis
We’re tracking 66 recruiting lymphoma studies with a site in or near St. Louis — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near St. Louis
- NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
St Louis, MissouriAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
St Louis, MissouriAges Up to 25 years - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
St Louis, MissouriAges 1–21 - NCT05388006RecruitingPhase 2
Testing three medicines for Richter transformation in CLL/SLL
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
St Louis, MissouriAges 18 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
St Louis, MissouriAges 18 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
St Louis, MissouriAges Up to 22 years - NCT04996706Enrolling by invitation
Studying lymphoma prognosis and survivorship in newly diagnosed patients
This study collects health information from people recently diagnosed with lymphoma to learn more about how the disease progresses and how to improve long-term well-being. It does not test a new treatment but helps researchers better understand what affects survival and quality of life.
St Louis, MissouriAges 18 years+ - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
St Louis, MissouriAges 18 years+ - NCT05976763RecruitingPhase 3
Testing continuous vs. intermittent zanubrutinib for older adults with mantle cell lymphoma
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
St Louis, MissouriAges 60 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
St Louis, MissouriAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
St Louis, MissouriAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
St Louis, MissouriAges 18 years+ - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Swansea, IllinoisAges 18 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Bridgeton, MissouriAges 18 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Alton, IllinoisAges 18 years+ - NCT06549595RecruitingPhase 3
Testing a new drug combo for untreated follicular lymphoma
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Chesterfield, MissouriAges 18–130 - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Chesterfield, MissouriAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Chesterfield, MissouriAges 18 years+
Hear when a new Lymphoma trial opens near St. Louis, MO
We’ll email you when one opens near St. Louis, MO — at most once a week, no account needed, unsubscribe anytime.
Lymphoma trials in other cities
Where these studies are running near St. Louis
Institutions with a site for the recruiting lymphoma studies listed above.
- Washington University in St. Louis · 10 studies
- Mercy Hospital Saint Louis · 3 studies
- Siteman Cancer Center · 3 studies
- Cancer Care Center of O'Fallon · 2 studies
- Memorial Hospital East · 2 studies
- OSF Saint Anthony's Health Center · 2 studies
- Saint Luke's Hospital · 2 studies
- Siteman Cancer Center at Saint Peters Hospital · 2 studies
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lymphoma studies in Missouri.
Common questions
- Are there lymphoma clinical trials near St. Louis?
- Yes. We're currently tracking 66 recruiting lymphoma studies with a site near St. Louis, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study near St. Louis?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in St. Louis to take part?
- Not necessarily. These studies have a site near St. Louis, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open near St. Louis regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.